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The epidemiology of rabies in the United States has changed substantially during the
last half century, as the source of the disease has changed from domesticated animals
to wildlife, principally raccoons, skunks, foxes, and bats. Moreover, the changes
observed among affected wildlife populations have not occurred without human influ-
ence. Rather, human attraction to the recreational and economic resources provided by
wildlife has contributed to the reemergence of rabies as a major zoonosis. Although
human deaths caused by rabies have declined recently to an average of one or two per
year, the estimated costs associated with the decrease in deaths amount to hundreds
of millions of dollars annually. In future efforts to control rabies harbored by free-ranging
animal reservoirs, public health professionals will have to apply imaginative, safe, and
cost-effective solutions to this age-old malady in addition to using traditional measures.
Rabies virus is the type species (serotype 1) of
the Lyssavirus genus, a group of morphologically
similar, antigenically and genetically related,
negative-stranded RNA viruses, with a near
global distribution (1). The lyssaviruses (Table 1)
are well adapted to particular mammalian spe-
cies (2) and rarely initiate panzootics. The public
health threat of rabies as a preeminent zoonosis
relates to the acute, incurable encephalitis that
results from transmission of the virus by the bite
of an infected animal. An estimated 40,000 to
100,000 human deaths are caused by rabies each
year worldwide; in addition, millions of persons,
primarily in developing countries of the subtropi-
cal and tropical regions (3), undergo costly postex-
posure treatment (PET). Although the number of
human rabies cases has been significantly re-
duced in the United States, the total number of
animal rabies cases approached historical limits
in 1993. To appreciate the public health signifi-
cance that lyssaviruses continue to play as per-
sistent and emerging infectious agents, one must
understand certain human activities, such as re-
cent animal translocations (i.e., the natural or
purposeful change by humans of  the normal
home range or geographic distribution of an ani-
mal) and animal ecology.
Historical Perspectives
The history of rabies in the New World reflects
the interaction of chance, evolutionary con-
straint, ecologic opportunism, and human sur-
veillance activities. Rabies may have existed in
the United States before European colonization
and the introduction of domestic animals incubat-
ing the disease. Various pathogens could have
migrated during the exchanges of fauna and hu-
man populations over the Bering Strait some
50,000 years ago; folklore of a rabies-like malady
among native people throughout the Pacific
Northwest supports this notion (4). Records at the
time of the Spanish conquest in Middle America
associate vampire bats with human illness (5). If
chiropteran rabies viruses were present and well
established in the New World at the time of con-
tinental interchange, terrestrial virus counter-
parts also could have been present. Nonetheless,
the first indication of terrestrial rabies did not
surface until 1703 in what is now California (5).
Dog and fox rabies outbreaks, reported commonly
in the mid-Atlantic colonies throughout the late
1700s (4), were probably exacerbated by the intro-
duction of dogs and red foxes (Vulpes vulpes),
imported for British-style fox hunting, through-
out New England in the 1800s; fox rabies epizo-
otics ensued and spread to the eastern United
States by the 1940s to 1950s (5,6). Skunk rabies
reports were also frequent throughout the west-
ern states by the 19th century, and they were
replete with cowboy tales of “phobey cats” (5).
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incidence of dog rabies at the beginning of the last
century, no national surveillance system existed.
Human deaths from rabies in the United States
were not commonly reported; the highest official
record was of 143 cases, from a survey of death
certificates in 1890. During 1938, when rabies in
humans and other animals became a nationally
reportable disease, the total number of rabies
cases reported was 9,412 per year (mostly in
domesticated species), with 47 human deaths.
These numbers are certainly underestimates,
since surveillance was limited, and sensitive
diagnostic tests for human and animal rabies
were not developed until the mid-1950s.
An epizootiologic transition began in the
United States in the 1920s, when rabies
prevention efforts were no longer focused exclu-
sively on human vaccination but began to include
programs for the control of rabies in dogs. Domes-
tic animal cases gradually declined, largely as a
result of local dog rabies control programs that
included vaccination, stray animal removal, and
leash and muzzle ordinances. However, as such
cases decreased, surveillance systems designed to
track the source of infection for residual domestic
animal foci detected increased cases in wild spe-
cies. By 1960, rabies was diagnosed more fre-
quently among wildlife than among domesticated
animals. In 1971, rabies was reported for the first
time from all 48 contiguous states and Alaska.
Skunks (primarily the striped skunk, Mephitis
mephitis) formed the major animal reservoir from
1961 to 1989, until they were unexpectedly sup-
planted by the raccoon (Procyon lotor) during the
rabies outbreak in the mid-Atlantic and north-
eastern states (7). This epizootic is believed to
have started during the late 1970s by the
Table 1. Recognized members of the genus Lyssavirus, family Rhabdoviridae
Lyssavirus Reservoir History
Rabies Found worldwide, except for a few island
nations, Australia, and Antarctica.
Endemic and sometimes epidemic in a
wide variety of mammalian species,
including wild and domestic canids,
mustelids, viverrids, and insectivorous
and hematophagous bats; >25,000 human
cases/year, almost all in areas of
uncontrolled domestic dog rabies.
Descriptions of clinical disease in Greek
and Roman documents. In the late 1800s,
Pasteur attenuated the virus by serial
passage and desiccation to vaccinate
humans and animals. Pathognomonic
inclusions in nerve cells described by
Negri in 1903. An immunofluorescence
test for rabies viral antigen developed in
the 1950s.
Lagosbat Unknown, but probably fruit bats. 10
cases identified to date, including 3 in
domestic animals, in Nigeria, South
Africa, Zimbabwe, Central African
Republic, Senegal, and Ethiopia. No
known human deaths.
Isolated in 1956 from brain of Nigerian
fruit bats (Eidolon helvum) at Lagos
Island, Nigeria, but not characterized
until 1970; 3 cases in domestic animals
initially diagnosed as rabies, but weak
immunofluorescence led to suspicion of
“rabies-related” virus, later confirmed by
typing with monoclonal antibodies or
nucleotide sequence analysis. Marginal
cross-protection with rabies vaccines.
Mokola Unknown, but probably an insectivore or
rodent species. Cases identified in
Nigeria, South Africa, Cameroon,
Zimbabwe, Central African Republic, and
Ethiopia; 17 cases known, including 9
domestic animals and 2 human cases.
First isolated from Crocidura sp. shrews
trapped in Mokola Forest near Ibadan,
Nigeria, in 1968. Characterized in 1970.
Like Lagos bat virus, evidence of infection
with Mokola was recognized only by poor
reaction with anti-rabies reagents. 7
domestic animal cases in Zimbabwe in
1981 and 1982 prompted serologic survey
and identification of antibodies to Mokola
in rodents, especially bushveld gerbils
(Tatera leucogaster). No cross-protection
with rabies vaccines.
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eastern focus of the disease.
The epidemiology of human rabies has also
changed considerably over the last 50 years (8,9).
From 1946 to 1965, 70% to 80% of human rabies
cases occurred after a known exposure (most
often a dog bite), and 50% of the cases before 1975
occurred after treatment with suboptimal vac-
cines. Over the last decade, 80% of rabies-related
human deaths were among persons who had no
definitive history of an animal bite (Table 2), and
none resulted from postexposure prophylaxis fail-
ures. Almost all the recent human cases occurred
after an animal exposure that was unrecognized
by the patient as carrying a risk for rabies infec-
tion. The apparent source of human rabies has
also changed: 14 of the 18 cases acquired in the
United States since 1980 involved rabies variants
associated with insectivorous bats (10).
The latest report, in March 1995, typifies re-
cent trends. A bat, subsequently found to be rabid,
was found in the bedroom of a 4-year-old girl in
Washington State. The child denied any contact
with the bat, and no postexposure treatment was
initiated. A bat-associated rabies virus variant
was later identified in biopsy specimens from the
Table 1. (continued)
Lyssavirus Reservoir History
Duvenhage Unknown, but probably insectivorous
bats. Cases identified in South Africa,
Zimbabwe, and Senegal; 4 cases known,
including 1 human death. No cases in
domestic animals.
First identified in 1970 in rabies-like
encephalitis in man bitten by an
insectivorous bat near Pretoria, South
Africa. Virus named after the victim.
Although Negri bodies detected in
histologic examination of brain tissue,
negative immunofluorescence tests led to
suspicion of rabies-related virus,
subsequently confirmed by antigenic and





European insectivorous bats (probably
Eptesicus serotinus); >400 cases in bats. 1
confirmed human case in 1985 and a
suspect case in 1977. No known domestic
animal cases.
Although cases in European bats were
reported as early as 1954, identification of
the virus was not attempted until 1985,
when the first of 100 infected bats was
reported in Denmark and Germany.
Almost all cases are in the common
European house bat, E serotinus.





European insectivorous bats (probably
Myotis dasycneme); 5 cases identified,
including 1 human death. No known
domestic animal cases.
First identified in isolate from Swiss bat
biologist who died of rabies in Finland.
Marginal cross-protection with rabies
vaccines.
Table 2. Human rabies cases in the United States by exposure
category, 1946-1995*                      
  Exposure  source       Case
Years Domestic Wildlife Other Unknown (%)  total    
1946-1955 86 8 0 26 (22) 120
1956-1965 21 7 0 10 (26)   38
1966-1975  6 7 1  2  (13)  16
1976-1985  6 1 2  11  (55)  20
1986-1995*   2 2 0 14  (78)  18
* Through Oct. 1995.
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current prominence of raccoons as the largest
wildlife reservoir in the United States (12), no
documented human rabies cases have been
associated with this ubiquitous carnivore.
The Cost of Prevention
Rabies prevention and control strategies in the
United States have succeeded in lowering the
number of human rabies deaths to an average of
one to two per year. However, the reason for this
low mortality level is a prevention program esti-
mated to cost $230 million to $1 billion per year
(13-15). This cost is shared by the private sector
(primarily the vaccination of companion animals)
and by the public (through animal control pro-
grams, maintenance of rabies laboratories, and
subsidizing of rabies PET).
Accurate estimates of these expenditures are
not available. The number of PETs given an-
nually in the United States is unknown, although
the total must be substantially greater than the
minimum of 20,000 estimated in 1980 to 1981 (16)
when vaccine distribution was more tightly
regulated. As rabies becomes epizootic or enzootic
in a region, the number of PETs increases (17).
Although the cost varies, a course of rabies immu-
noglobulin and five doses of vaccine given over a
4-week period typically exceeds $1,000. Potential
exposure to a single rabid kitten in New Hamp-
shire recently led to the treatment of more than
650 persons at an estimated cost of $1.5 million
(18). Surveillance-related costs also rise as rabies
becomes entrenched in wildlife. During 1993, the
New York State rabies diagnostic laboratory re-
ceived approximately 12,000 suspected animal
submissions. This compares with approximately
3,000 submissions in 1989, before raccoon rabies
became epizootic. In New Jersey, rabies preven-
tion expenditures in two counties increased from
$768,488 in 1988, before the raccoon epizootic, to
$1,952,014 in 1990, the first full year of the
epizootic (15); vaccination of pet animals ac-
counted for 82% of this total. Vaccinated domestic
animals are normally administered a booster vac-
cine dose after a known or suspected rabid animal
exposure (19). This further increases costs, as
wildlife rabies epizootics escalate. The cost per
human life saved from rabies ranges from ap-
proximately $10,000 to $100 million, depending
on the nature of the exposure and the probability
of rabies in a region (20).
What’s more, most economic analyses do not
take into account the psychological trauma
caused by human exposure to rabies, the sub-
sequent euthanasia of pets, or the loss of wildlife
resources during rabies outbreaks. Rabies in
wildlife has now reached historically high levels
in the United States (12), and the costs of prevent-
ing human rabies are mounting.
Human Influences and the Role of Translocation
The colonization of the New World had a pro-
found effect upon native fauna and consequent
rabies epizootiology. Large-bodied carnivores,
such as bears, cougars, wolves, and wolverines,
were perceived as dangerous and killed outright.
A few Carnivora have persisted and flourished.
For example, the coyote (Canis latrans), a highly
adaptable canid and the subject of many unsuc-
cessful control programs, has been gradually ex-
panding its range northward and eastward.
Despite their widespread distribution and abun-
dance (even in suburban neighborhoods), rabid
coyotes have been reported rarely and
sporadically, except for a brief period from 1915
to 1917, when an extensive outbreak occurred in
portions of Utah, Nevada, California, and Oregon.
While dog rabies has been largely controlled, a
region of southern Texas that borders Mexico has
persisted as a focus of both dog and coyote rabies.
The number of cases of coyote rabies has gradu-
ally risen in this area since the late 1980s, ac-
counting for 46 of the 50 cases of coyote rabies
reported in the United States during 1991, 70 of
75 cases in 1992, and 71 of 74 cases in 1993 (12).
The outbreak of coyote rabies has spread to the
vicinity of San Antonio. One of the dangers of this
outbreak is the continued spillover into the do-
mestic dog population (21); at least 25 rabid dogs
were reported from the area in 1991, 41 in 1992,
and 54 in 1993 (12). Human rabies closely paral-
lels the disease in domestic animals; at least two
human deaths (in 1991 and 1994), probably due
to coyote-dog interactions, have been associated
with this canid outbreak in Texas (10,22).
The translocation of infected coyotes from the
south Texas focus is believed to be responsible for
the transmission of this rabies variant to dogs in
at least two other states: a single hunting dog in
Alabama during 1993 (12) and at least seven
cases of apparent dog-to-dog rabies transmission
in Florida in 1994 (21). Expanded surveillance
similar to that done in 1977 with the raccoon
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ranted for this canid virus. In this effort, state
health departments should monitor unusual oc-
currences (such as the increased submission of
canid specimens to the diagnostic facility), track-
ing of their time and location, and establishment
of suitable public health interventions. These
would include restricting further animal move-
ments and enforcing mandatory companion ani-
mal rabies vaccination. Assessing control efforts
is an important component of any intervention.
In addition to the problems posed by the emer-
gence of the coyote as a reservoir for rabies, the
potential translocation of other species should be
recognized.
Since the transmission of rabies by a bat was
first reported in 1953, rabid insectivorous bats
have caused an average of 700 to 800 cases annu-
ally, and have been found throughout the United
States, excluding Alaska and Hawaii (12). The
discovery of these cases, coincident with the
marked reduction of canine rabies cases, has af-
forded a certain epidemiologic luxury to enhance
surveillance among wildlife. Similar to the
Carnivora, the chiropteran families most impor-
tant in rabies perpetuation (e.g., Vespertilionidae,
Molossidae) have several species that are highly
adaptable, abundant, and widespread. Rabies vi-
rus variants maintained by insectivorous bats
appear to be exchanged largely independently
from those in terrestrial mammalian reservoirs
(23), despite documented spillovers. A similar
epidemiologic situation exists among European
bats, but with Lyssavirus genotypes (24) that can
be readily differentiated from New World rabies
isolates. The role of bats in Africa (25,26) in Lys-
savirus maintenance is less clear (Table 1). Infec-
tions with non-rabies lyssaviruses have resulted
in rabies vaccine failures (27). Such infections
raise the specter of potentially serious public health
consequences if introduced and subsequently es-
tablished in susceptible bat populations. How
probable is this scenario?
The distances between Africa, Eurasia, Pacific
Oceania, and the New World mitigate against the
dispersal, migration, and introduction of healthy
bats without human intervention (28). However,
several recent events illustrate the opportunity
for the transoceanic transfer of rabies-infected
bats. In March 1986, researchers from Canada
inadvertently shipped a big brown bat (Eptesicus
fuscus) that was incubating rabies virus to
colleagues in Tubingen, Germany. When the bat
became ill and was euthanized, a diagnosis of
rabies was made (29). A similar event occurred
when Boston researchers collected a dozen wild
big brown bats from Massachusetts during July
1994 and exported them to researchers in Den-
mark. By December 1994, six of the imported bats
had died and were confirmed as positive for rabies
virus by the Danish Veterinary Services, State
Institute for Virus Research (L. Miller, pers.
comm.).
Commercial enterprises also serve as vehicles
for the accidental translocation of animals in-
fected with rabies virus. The first confirmed non-
indigenous case of rabies in Hawaii resulted from
the accidental introduction of a big brown bat
(30). In March 1991, a bat was captured within a
transport container unloaded from a ship in
Honolulu harbor. The container held automobiles
from Michigan loaded into the container ship in
California. The local department of health labo-
ratory diagnosed rabies; this was later confirmed,
and the virus was characterized antigenically at
the Centers for Disease Control and Prevention.
The strain was a variant common to E. fuscus in
the midwestern and western United States. None
of the three instances cited above appear to have
resulted in secondary cases or establishment of
the virus in foreign animal populations.
No unintended importations of non-rabies lys-
saviruses to the United States have been docu-
mented. The likelihood of accidental introduction,
escape, survival, and perpetuation of infected ex-
otic bat species into the United States is remote.
However, other more recent deliberate transloca-
tion activities may significantly enhance the
probability of such introductions.
During 1994, a number of improperly issued
federal permits allowed as many as several thou-
sand wild bats to be imported to the United States
for sale in the commercial pet trade. These
animals were primarily Egyptian tomb bats
(Rousettus aegyptiacus), although several other
bat species were imported as well. Sales of im-
ported bats (and their offspring) to private collec-
tors or as pets in the United States are prohibited,
according to the Foreign Quarantine Regulations
(42 CFR 71.54). Animals that may be vectors of
diseases of public health concern are eligible for
entrance only for restricted uses at accredited
zoos or research institutions, where contact with
the general public is limited. Imported bats that
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extended quarantine period.
Although no reports of lyssaviruses isolated
from Egyptian fruit bats exist, active surveillance
for such viruses has not been conducted. These
bats are relatively common and widespread
throughout the area that extends from Turkey
and Cyprus to Pakistan, the Arabian peninsula,
Egypt, and most of sub-Saharan Africa (31). Be-
cause they may roost by the thousands in a wide
variety of habitats, there is ample opportunity for
interaction with other Chiroptera, such as the
widely distributed straw-colored (Eidolon
helvum) or epauletted (Epomophorus wahlbergi)
fruit bats; both of these species have been impli-
cated in Lyssavirus epizootiology in Africa (25,26).
The adaptability of Egyptian fruit bats should be
a cause for concern because of the potential for
survival and interaction among indigenous bat
fauna, particularly in the southern United States.
Additionally, beyond the obvious public health
risks and foreign animal disease introduction,
imported bat species should not be released into
the wild because they may cause serious harm to
local agriculture and may displace native species.
Bats serve many critical ecologic functions
worldwide and generally avoid contact with hu-
mans. However, they may be infected with many
pathogens without demonstrating obvious clini-
cal signs of infection. When bats are placed in a
private household or pet shop, the hazard of dis-
ease transmission to humans is greatly increased.
Persons currently possessing imported bats
should be advised not to display them in settings
where human contact can occur.
Intervention
Widespread, sustained population reduction of
mammalian reservoirs to eliminate rabies is not
justified (32) for ecologic, economic, and ethical
reasons. Given the multispecies complexity and
considerable geographic areas affected by wildlife
rabies, and the opportunities for translocation,
what alternative preventive strategies exist? Re-
cent progress in implementing terrestrial wildlife
rabies control programs elsewhere in the world
has public health relevance for the United States.
Oral rabies vaccination of the red fox with vac-
cine-laden baits is an integral aspect of rabies
control throughout southeastern Canada and
Europe, where more than 75 million doses of
vaccine have been distributed over 5 million km
2
during the past two decades (33). Consequently,
rabies incidence among wild and domestic ani-
mals has fallen, as have PETS for human rabies.
The raccoon rabies epizootic in the eastern
United States provided renewed impetus for re-
considering oral vaccination technology, first con-
ceived at the Center for Disease Control in the
1960s (34). The shift of the vaccination and bait-
ing methods from a fox model to the raccoon
involved extensive field and laboratory research
during the 1980s. The existing attenuated rabies
vaccines for foxes were shown to be less effective
for raccoons and other carnivores (35,36). Addi-
tionally, studies of new candidate vaccines raised
safety issues regarding vaccine-induced disease
in wildlife (36).
In 1983, a vaccinia-rabies glycoprotein (V-RG)
recombinant virus vaccine was developed (37)
that has proven to be an effective oral immunogen
in raccoons and various other important reservoir
species (38); vaccine advantages include im-
proved thermostability and an inability to cause
rabies. (Only the gene for the surface glycoprotein
of a vaccine strain of rabies virus was included in
the recombinant virus.) When vaccine-laden baits
are offered under natural conditions, contact with
them by nontarget wildlife species cannot be to-
tally excluded. However, studies of V-RG virus
have shown no vaccine-associated morbidity, mor-
tality, or gross pathologic lesions in more than 40
warm-blooded vertebrate species examined.
Moreover, with rare exceptions, there has been no
contact-transfer of vaccine between vaccinated
and control animals housed together (38); viral
recovery has been limited to a few anatomical
sites over a 48-h interval (39).
While laboratory evaluations of target and
nontarget species proceeded during 1987 to 1989,
small-scale trials of V-RG were conducted in Bel-
gium and France, with promising results (40).
The first North American V-RG vaccine field trial
began on August 20, 1990, on Parramore Island
off the eastern shore of Virginia (41,42). This
limited field trial demonstrated vaccine safety.
Efficacy was also suggested: more than 80% of
field-vaccinated raccoons survived a severe labo-
ratory rabies challenge (7 months after V-RG
release) to which more than 90% of control rac-
coons succumbed (43).
A 1991 Pennsylvania study site closely ap-
proximated the ecologic communities of the east-
ern United States targeted for use of V-RG
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rity through its geographic barriers. The study at
this site evaluated the rate of vaccine-laden bait
contact and potential vaccine-related adverse ef-
fects among nonraccoon species, including ro-
dents, carnivores, insectivores, and opossum.
Raccoons and other furbearers demonstrated no
adverse effects associated with vaccine contact.
Examination of more than 750 nontarget indi-
viduals, representing 35 species, failed to demon-
strate gross lesions suggestive of V-RG contact.
After these safety trials, the first efficacy field
experiments began in New Jersey during 1992
(44). Between spring 1992 and autumn 1994,
more than 100,000 vaccine-laden fishmeal poly-
mer baits were distributed by hand and helicopter
over an area of 56,000 hectares. This trial at-
tempted to create a population of immunized rac-
coons across the northern Cape May Peninsula to
prevent the spread of epizootic raccoon rabies
from affected portions of the state. Surveillance
demonstrated a significant decrease in the rate of
spread and overall rabies incidence in the target
and other monitored areas (44), suggesting the
potential effectiveness of this strategy.
In the United States, oral vaccination of rac-
coons is now under way in Massachusetts (45),
New York (46), and Florida, and an experimental
extension of the program to coyotes is under way
in south Texas. However, the future of such vac-
cination for wildlife in the United States may be
seriously questioned. For oral vaccination to
become an adjunct to traditional methods, the
following major questions need to be answered:
1) What is the relationship between animal popu-
lation density and the minimum density of vac-
cine/baits needed? 2) What level of herd immunity
is necessary to eliminate rabies under various
environmental circumstances? 3) What bait dis-
tribution techniques are optimal? 4) How can
these methods be generalized from foxes and rac-
coons to other species, such as skunks, mongooses
and dogs? 5) What long-term funding sources are
available? 6) What are the various costs of rabies
control and prevention methods? Given the prob-
lems inherent in wildlife control, the greater issue
of extending these methods to the control of dog
rabies in the developing world will be a challenge
well into the next century.
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